Return to site

Study Investigates Cost Effectiveness of New HCV Treatments

by Robert Hindes MD

Robert Hindes, MD, is the cofounder and chief medical officer of Trek Therapeutics, a Benefit corporation currently working on affordable treatments for hepatitis C virus (HCV) infections. As an HCV researcher and leader in the drug-discovery industry, Robert Hindes, MD, closely follows the latest studies and research on HCV.
In a recent study funded by the National Foundation for the Centers for Disease Control and Prevention, researchers investigated the cost effectiveness of new HCV treatments, which deliver significantly higher cure rates, fewer contraindications, and reduced side effects compared to past HCV treatments. The study found that new HCV treatments are cost effective for the population of patients treated, but the cost was still prohibitive for many individuals infected with HCV.
It is the goal of Trek Therapeutics to increase access to these "cost effective" therapies so that many more patients can benefit from these treatments.
All Posts
×

Almost done…

We just sent you an email. Please click the link in the email to confirm your subscription!

OKSubscriptions powered by Strikingly